1-Bromo-2,4,6-trifluorobenzene

We are 1-Bromo-2,4,6-trifluorobenzene CAS:2367-76-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1-Bromo-2,4,6-trifluorobenzene
CAS.NO:2367-76-2
Synonyms:1-Bromo-2,4,6-trifluorobenzene
1-BroMo-2,4,6-trifluorobenzene
2,4,6-trifluorophenyl bromide
2,4,6-TRIFLUOROBROMOBENZENE
Molecular Formula:C6H2BrF3
Molecular Weight:210.97900
 
Physical and Chemical Properties:
Density:1.79
Melting point:3.5ºC
Boiling point:140.5ºC
Flash point:137°F
Index of Refraction:1.485
 
Specification:
Appearance:Colorless liquid
Assay:≥99.0%
Moisture:≤0.2%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

1-Bromo-2,4,6-trifluorobenzene


Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.4-Biphenylboronic acid CAS:5122-94-1 As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.5-Bromo-2-fluorobenzoic acid CAS:146328-85-0 From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.FENOL 2-BROMO-5- (TRIFLUOROMETHOXY) CAS:205371-26-2 From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
Ramoplanin View Details
8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione View Details
2,5-Diaminoanisole sulfate View Details
5-Bromo-2-fluorotoluene manufacturer 2-aminonicotinic acid manufacturer 2-Amino-4-bromobenzoic acid manufacturer (4S,5R)-3-Benzoyl-2-(4-methoxyphenyl)-4-phenyloxazolidine-5-carboxylic acid manufacturer 4-Fluoro-3-nitrotoluene manufacturer